These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 23118670)

  • 1. The pharmacokinetics of oseltamivir and oseltamivir carboxylate in a critically ill pediatric patient receiving extracorporeal membrane oxygenation and continuous venovenous hemodialysis.
    Eyler RF; Klein KC; Mueller BA
    J Pediatr Pharmacol Ther; 2012 Apr; 17(2):173-6. PubMed ID: 23118670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.
    Eyler RF; Heung M; Pleva M; Sowinski KM; Park PK; Napolitano LM; Mueller BA
    Pharmacotherapy; 2012 Dec; 32(12):1061-9. PubMed ID: 23208833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza.
    Lemaitre F; Luyt CE; Roullet-Renoleau F; Nieszkowska A; Zahr N; Corvol E; Fernandez C; Antignac M; Farinotti R; Combes A
    Ther Drug Monit; 2012 Apr; 34(2):171-5. PubMed ID: 22354159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support.
    Mulla H; Peek GJ; Harvey C; Westrope C; Kidy Z; Ramaiah R
    Anaesth Intensive Care; 2013 Jan; 41(1):66-73. PubMed ID: 23362894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support.
    Wildschut ED; de Hoog M; Ahsman MJ; Tibboel D; Osterhaus AD; Fraaij PL
    PLoS One; 2010 Jun; 5(6):e10938. PubMed ID: 20532176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.
    Ariano RE; Sitar DS; Zelenitsky SA; Zarychanski R; Pisipati A; Ahern S; Kanji S; Rello J; Kumar A
    CMAJ; 2010 Mar; 182(4):357-63. PubMed ID: 20159892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v.
    Petersen E; Keld DB; Ellermann-Eriksen S; Gubbels S; Ilkjær S; Jensen-Fangel S; Lindskov C
    Scand J Infect Dis; 2011 Jul; 43(6-7):495-503. PubMed ID: 21309638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy.
    Karsch K; Chen X; Miera O; Peters B; Obermeier P; Francis RC; Amann V; Duwe S; Fraaij P; Heider A; de Zwart M; Berger F; Osterhaus A; Schweiger B; Rath B
    Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):155-164. PubMed ID: 26994602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oseltamivir Dosing in Critically Ill Patients With Severe Influenza.
    Flannery AH; Thompson Bastin ML
    Ann Pharmacother; 2014 Aug; 48(8):1011-1018. PubMed ID: 24816209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracorporeal membrane oxygenation for severe refractory respiratory failure secondary to 2009 H1N1 influenza A.
    Turner DA; Rehder KJ; Peterson-Carmichael SL; Ozment CP; Al-Hegelan MS; Williford WL; Peters MA; Noble PW; Cheifetz IM
    Respir Care; 2011 Jul; 56(7):941-6. PubMed ID: 21352668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.
    Widmer N; Meylan P; Ivanyuk A; Aouri M; Decosterd LA; Buclin T
    Clin Pharmacokinet; 2010 Nov; 49(11):741-65. PubMed ID: 20923248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary.
    Pai MP; Lodise TP
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5640-5. PubMed ID: 21930881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients.
    Hahn J; Choi JH; Chang MJ
    J Clin Pharm Ther; 2017 Dec; 42(6):661-671. PubMed ID: 28948652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support.
    Cies JJ; Moore WS; Dickerman MJ; Small C; Carella D; Chopra A; Parker J
    Pharmacotherapy; 2014 Oct; 34(10):e175-9. PubMed ID: 25146254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil gelatinase-associated lipocalin levels during extracorporeal membrane oxygenation in critically ill children with congenital heart disease: preliminary experience.
    Ricci Z; Morelli S; Favia I; Garisto C; Brancaccio G; Picardo S
    Pediatr Crit Care Med; 2012 Jan; 13(1):e51-4. PubMed ID: 21057360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recommendations of the Infectious Diseases Work Group (GTEI) of the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC) and the Infections in Critically Ill Patients Study Group (GEIPC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) for the diagnosis and treatment of influenza A/H1N1 in seriously ill adults admitted to the Intensive Care Unit].
    Rodríguez A; Alvarez-Rocha L; Sirvent JM; Zaragoza R; Nieto M; Arenzana A; Luque P; Socías L; Martín M; Navarro D; Camarena J; Lorente L; Trefler S; Vidaur L; Solé-Violán J; Barcenilla F; Pobo A; Vallés J; Ferri C; Martín-Loeches I; Díaz E; López D; López-Pueyo MJ; Gordo F; del Nogal F; Marqués A; Tormo S; Fuset MP; Pérez F; Bonastre J; Suberviola B; Navas E; León C; ; ;
    Med Intensiva; 2012 Mar; 36(2):103-37. PubMed ID: 22245450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit.
    Giraud C; Manceau S; Oualha M; Chappuy H; Mogenet A; Duchêne P; Ducrocq S; Hubert P; Treluyer JM
    Antimicrob Agents Chemother; 2011 Jan; 55(1):433-5. PubMed ID: 20937783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis.
    Robson R; Buttimore A; Lynn K; Brewster M; Ward P
    Nephrol Dial Transplant; 2006 Sep; 21(9):2556-62. PubMed ID: 16799169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous Ribavirin for Parainfluenza and Respiratory Syncytial Virus in an Infant Receiving Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy.
    Sargel CL; Aboud M; Forster A; Langman LJ; Tansmore J; Mueller BA; Smoyer WE; Auletta JJ
    J Pediatr Pharmacol Ther; 2018; 23(4):337-342. PubMed ID: 30181726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.